3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Lymphoid
1
Conditions
Squamous Cell Carcinoma of Head and Neck
2
Neoplasms
2
Vascular Diseases
1
Pathologic Processes
1
Paraproteinemias
1
Pancreatic Neoplasms
1
Neoplastic Processes
1
Neoplasms, Plasma Cell
1
Neoplasms by Site
1
Neoplasms by Histologic Type
1
Neoplasm Metastasis
1
Multiple Myeloma
1
Lymphoproliferative Disorders
1
Lymphoma
1
Lymphatic Diseases
1
Liver Neoplasms
1
Liver Diseases
1
Leukemia, Myeloid, Acute
1
Immunoproliferative Disorders
1
Hemorrhagic Disorders
1
Hematologic Diseases
1
Gliosarcoma
1
Glioblastoma
1
Digestive System Neoplasms
1
Digestive System Diseases
1
Cardiovascular Diseases
1
Carcinoma
1
Blood Protein Disorders
1
Interventions
Rituximab
57
Cyclophosphamide
56
fludarabine
37
fludarabine phosphate
31
Filgrastim
27
Etoposide
22
Bortezomib
20
Melphalan
19
Gemcitabine
19
Cytarabine
17
Bendamustine Hydrochloride
17
Peripheral Blood Stem Cell Transplantation
16
Vincristine
15
pembrolizumab
14
aldesleukin
13
Prednisone
13
Doxorubicin
12
Dexamethasone
12
Busulfan
12
Whole-Body Irradiation
11
Vorinostat
11
Tacrolimus
11
Sirolimus
11
sargramostim
10
obinutuzumab
10
Lenalidomide
10
romidepsin
9
Radiotherapy
9
Rifampin
8
Paclitaxel
8
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Lymphoma
×
ficlatuzumab
×
Clear all
NCT00725634
2014-01-27
P05538
AVEO Pharmaceuticals, Inc.
Phase 1
Completed
41 enrolled